BD Announces Results For 2014 Second Fiscal Quarter

- Announces revenues of $2.072 billion, an increase of 3.6 percent, or 5.1 percent on a foreign currency-neutral basis.

- Reports adjusted diluted earnings per share from continuing operations of $1.53, an increase of 10.1 percent, or 15.8 percent on a foreign currency-neutral basis. Reported diluted earnings per share from continuing operations were $1.45.

01 May, 2014, 06:00 ET from BD (Becton, Dickinson and Company)

FRANKLIN LAKES, N.J., May 1, 2014 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.072 billion for the second fiscal quarter ended March 31, 2014, representing an increase of 3.6 percent from the prior-year period, or 5.1 percent on a foreign currency-neutral basis.

"We are pleased with our solid second quarter and year-to-date results," said Vincent A. Forlenza, Chairman, CEO and President. "Revenues were driven by the Medical segment and continued improvement in our Biosciences segment. This consistent performance demonstrates the breadth of the growth drivers across our businesses and regions, and highlights the diversity of our portfolio."

Second Quarter and Six-Month Fiscal 2014 Operating Results

Reported diluted earnings per share from continuing operations for the second quarter were $1.45 compared with $1.39 in the prior-year period, representing a 4.3 percent increase. On a foreign currency-neutral basis, diluted earnings per share from continuing operations for the second quarter increased by 10.1 percent. Current quarter results include pre-tax charges for asset write-offs of $20 million, or $0.06 diluted earnings per share from continuing operations, and contract termination costs of $11 million, or $0.04 diluted earnings per share from continuing operations, partially offset by a pre-tax gain on investment of $8 million, or $0.03 diluted earnings per share from continuing operations. Excluding the net impact of these items, adjusted diluted earnings per share from continuing operations were $1.53. This represents an increase of 10.1 percent, or 15.8 percent on a currency-neutral basis.

For the six-month period ending March 31, 2014, diluted earnings per share from continuing operations were $2.82, compared with $2.74 in the prior-year period. This represents growth of 2.9 percent, or 9.1 percent on a currency-neutral basis.  Excluding the first quarter incremental impact of the medical device excise tax, which went into effect in January 2013 under the U.S. Patient Protection and Affordable Care Act, adjusted diluted earnings per share from continuing operations were $2.94 compared with $2.74 in the prior-year period.  This represents growth of 7.3 percent, or 13.5 percent on a currency-neutral basis.

Segment Results

In the BD Medical segment, worldwide revenues for the quarter were $1.116 billion, representing an increase of 5.1 percent compared with the prior-year period, or an increase of 6.3 percent on a foreign currency-neutral basis. The segment's revenue growth reflects strong sales in the Diabetes Care unit and solid sales in the Medical Surgical Systems and Pharmaceutical Systems units.

For the six-month period ended March 31, 2014, BD Medical revenues increased 6.6 percent, or 7.4 percent on a currency-neutral basis.

In the BD Diagnostics segment, worldwide revenues for the quarter were $653 million, representing a decrease of 0.9 percent compared with the prior-year period, or an increase of 1.0 percent on a foreign currency-neutral basis. Solid sales in the Preanalytical Systems unit were partially offset by ongoing softness in Women's Health and Cancer in the U.S.

For the six-month period ended March 31, 2014, BD Diagnostics revenues increased 1.1 percent, or 2.6 percent on a currency-neutral basis.

In the BD Biosciences segment, worldwide revenues for the quarter were $302 million, representing an increase of 8.2 percent compared with the prior-year period, or an increase of 10.2 percent on a foreign currency-neutral basis. The segment's growth was driven by continued strength in emerging markets, solid instrument placements, a favorable comparison to the prior year and a timing of orders.

For the six-month period ended March 31, 2014, BD Biosciences revenues increased 6.8 percent, or 8.0 percent on a currency-neutral basis.

Geographic Results

Second quarter revenues in the U.S. of $826 million represent an increase of 0.2 percent over the prior-year period. Revenues outside of the U.S. were $1.246 billion, representing an increase of 5.9 percent compared with the prior-year period, or an increase of 8.5 percent on a foreign currency-neutral basis. International revenues reflected continued strength in emerging markets and sales of safety-engineered products.

For the six-month period ended March 31, 2014, revenues in the U.S. were $1.675 billion, representing an increase of 1.3 percent compared with the prior-year period. Revenues outside of the U.S. were $2.412 billion, representing an increase of 7.3 percent when compared with the prior-year period, or 9.2 percent on a foreign currency-neutral basis.

Fiscal 2014 Outlook for Full Year  

The Company reaffirms its previously communicated currency-neutral revenue guidance range of 4.5 to 5.0 percent. On a reported basis, the Company expects revenue growth of 4.0 to 4.5 percent. The Company is raising its previous guidance for diluted earnings per share from continuing operations for the full fiscal year 2014 to be between $6.14 and $6.17, or $6.22 and $6.25 excluding the impact of the previously mentioned second quarter adjustments. This represents growth of 7.0 to 7.5 percent over 2013 adjusted diluted earnings per share of $5.81.  On a foreign currency-neutral basis, adjusted diluted earnings per share are expected to grow about 10.0 to 10.5 percent, or 11.0 to 11.5 percent excluding the incremental impact of the medical device tax.  The Company plans to repurchase, subject to market conditions, about $450 million of its common stock in fiscal year 2014.

Conference Call Information

A conference call regarding BD's second quarter results will be broadcast live on BD's website, www.bd.com/investors, along with related slides, at 8:00 a.m. (ET) Thursday, May 1st, 2014.  The conference call will be available for replay on BD's website, www.bd.com/investors, or at 1-800-585-8367 (domestic) and 1-404-537-3406 (international) through the close of business on Thursday, May 8th, 2014, confirmation number 24652897.

Non-GAAP Financial Measures/Financial Tables

This news release contains certain non-GAAP financial measures.  Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables.  Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers.  Percentages and earnings per share amounts presented are calculated from the underlying amounts.

About BD

BD is a leading medical technology company that partners with customers and stakeholders to address many of the world's most pressing and evolving health needs. Our innovative solutions are focused on improving drug delivery, enhancing the diagnosis of infectious diseases and cancers, supporting the management of diabetes and advancing cellular research. We are nearly 30,000 associates in 50 countries who strive to fulfill our purpose of "Helping all people live healthy lives" by advancing the quality, accessibility, safety and affordability of healthcare around the world. For more information, please visit www.bd.com.

***

This press release, including the section entitled "Fiscal 2014 Outlook for Full Year", contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues and earnings per share.  All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties.  Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement.  With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially from any forward-looking statement.  These factors include, but are not limited to: potential cuts in healthcare spending by the U.S. government as part of deficit reduction measures which could result in reduced demand for our product or downward pricing pressure; the unknown consequences of healthcare reform in the United States, including the impact of the reduction in Medicare and Medicaid payments to hospitals, pharmaceutical companies and other customers, which could reduce demand for our products and increase downward pricing pressure; adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic conditions on our ability to access credit markets and finance our operations, the demand for our products and services as a result of reduced government funding, lower utilization rates or otherwise, or our suppliers' ability to provide products needed for our operations; changes in interest or foreign currency exchange rates; our ability to successfully integrate any businesses we acquire; the adverse impact of cyber-attacks on our information systems; competitive factors; pricing and market pressures; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; new or changing laws impacting our business or changes in enforcement practices with respect to such laws; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; and issuance of new or revised accounting standards, as well as other factors discussed in BD's filings with the Securities and Exchange Commission.  We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

Contact: Monique N. Dolecki, Investor Relations – 201-847-5453 Alyssa J. Zeff, Corporate Communications – 201-847-4358

 

BECTON DICKINSON AND COMPANY

CONSOLIDATED INCOME STATEMENTS

(Unaudited; Amounts in millions, except share and per share data)

Three Months Ended March 31,

2014

2013

% Change

REVENUES

$

2,072

$

2,000

3.6

Cost of products sold

1,019

982

3.7

Selling and administrative 

525

515

2.0

Research and development

147

122

20.0

TOTAL OPERATING COSTS

     AND EXPENSES

1,690

1,619

4.4

OPERATING INCOME

381

381

0.1

Interest income

10

12

(18.4)

Interest expense

(33)

(35)

(4.7)

Other income, net

5

2

        NM 

INCOME FROM CONTINUING OPERATIONS BEFORE

     INCOME TAXES

363

360

0.8

Income tax provision

76

84

(9.9)

INCOME FROM CONTINUING OPERATIONS

287

276

4.0

INCOME (LOSS) FROM DISCONTINUED OPERATIONS

   NET OF INCOME TAX PROVISION (BENEFIT) OF

   $0 AND $(1), RESPECTIVELY

-

-

 NM 

NET INCOME

$

287

$

276

4.2

EARNINGS PER SHARE

Basic:

Income from continuing operations

$

1.48

$

1.42

4.2

Income (loss) from discontinued operations

$

-

$

-

-

Net income

$

1.48

$

1.42

4.2

Diluted:

Income from continuing operations

$

1.45

$

1.39

4.3

Income (loss) from discontinued operations

$

-

$

-

-

Net income

$

1.45

$

1.39

4.3

AVERAGE SHARES OUTSTANDING (in thousands)

     Basic

193,609

194,609

     Diluted

197,488

198,143

NM - Not Meaningful

BECTON DICKINSON AND COMPANY

CONSOLIDATED INCOME STATEMENTS

(Unaudited; Amounts in millions, except share and per share data)

Six Months Ended March 31,

2014

2013

% Change

REVENUES

$

4,086

$

3,901

4.8

Cost of products sold

1,999

1,876

6.5

Selling and administrative 

1,056

1,010

4.5

Research and development

273

241

13.4

TOTAL OPERATING COSTS

     AND EXPENSES

3,327

3,127

6.4

OPERATING INCOME

759

773

(1.8)

Interest income

24

20

19.4

Interest expense

(67)

(70)

(4.5)

Other income, net

6

3

        NM 

INCOME FROM CONTINUING OPERATIONS BEFORE

     INCOME TAXES

722

726

(0.6)

Income tax provision

164

180

(9.0)

INCOME FROM CONTINUING OPERATIONS

558

546

2.2

INCOME FROM DISCONTINUED OPERATIONS

   NET OF INCOME TAX PROVISION OF

   $0 AND $215, RESPECTIVELY

-

355

        NM 

NET INCOME

$

558

$

901

(38.0)

EARNINGS PER SHARE

Basic:

Income from continuing operations

$

2.88

$

2.79

3.2

Income from discontinued operations

$

-

$

1.81

        NM 

Net income

$

2.88

$

4.61

(37.5)

Diluted:

Income from continuing operations

$

2.82

$

2.74

2.9

Income from discontinued operations

$

-

$

1.78

        NM 

Net income 

$

2.82

$

4.53

(37.7)

AVERAGE SHARES OUTSTANDING (in thousands)

     Basic

193,909

195,528

     Diluted

197,998

199,068

NM - Not Meaningful

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY SEGMENT AND GEOGRAPHIC AREA

(Unaudited; Amounts in millions)

Three Months Ended March 31,

2014

2013

% Change

BD MEDICAL

   United States

$

434

$

412

5.2

   International

682

650

5.0

TOTAL

$

1,116

$

1,062

5.1

BD DIAGNOSTICS

   United States

$

301

$

322

(6.4)

   International

352

337

4.5

TOTAL

$

653

$

659

(0.9)

BD BIOSCIENCES

   United States

$

90

$

89

1.4

   International

212

191

11.4

TOTAL

$

302

$

279

8.2

TOTAL REVENUES

   United States

$

826

$

824

0.2

   International

1,246

1,177

5.9

TOTAL

$

2,072

$

2,000

3.6

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY SEGMENT AND GEOGRAPHIC AREA

(Unaudited; Amounts in millions)

Six Months Ended March 31,

2014

2013

% Change

BD MEDICAL

   United States

$

875

$

838

4.5

   International

1,304

1,208

8.0

TOTAL

$

2,180

$

2,045

6.6

BD DIAGNOSTICS

   United States

$

622

$

643

(3.2)

   International

703

668

5.2

TOTAL

$

1,325

$

1,311

1.1

BD BIOSCIENCES

   United States

$

177

$

173

2.3

   International

404

371

8.9

TOTAL

$

581

$

544

6.8

TOTAL REVENUES

   United States

$

1,675

$

1,654

1.3

   International

2,412

2,247

7.3

TOTAL

$

4,086

$

3,901

4.8

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Three Months Ended March 31,

(Unaudited; Amounts in millions)

United States

2014

2013

 % Change 

BD MEDICAL

   Medical Surgical Systems

$

240

$

236

1.9

   Diabetes Care

118

107

10.3

   Pharmaceutical Systems

76

70

8.8

TOTAL

$

434

$

412

5.2

BD DIAGNOSTICS

   Preanalytical Systems

$

163

$

162

0.7

   Diagnostic Systems

138

160

(13.6)

TOTAL

$

301

$

322

(6.4)

BD BIOSCIENCES

$

90

$

89

1.4

TOTAL UNITED STATES

$

826

$

824

0.2

 

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Three Months Ended March 31, (continued)

(Unaudited; Amounts in millions)

International

 % Change 

2014

2013

 Reported 

FXN

FX Impact

BD MEDICAL

   Medical Surgical Systems

$

311

$

303

2.6

6.3

(3.7)

   Diabetes Care

133

125

6.2

10.5

(4.3)

   Pharmaceutical Systems

238

221

7.6

5.9

1.7

TOTAL

$

682

$

650

5.0

7.0

(2.0)

BD DIAGNOSTICS

   Preanalytical Systems

$

179

$

168

6.7

10.2

(3.5)

   Diagnostic Systems

173

169

2.3

6.0

(3.7)

TOTAL

$

352

$

337

4.5

8.1

(3.6)

BD BIOSCIENCES

$

212

$

191

11.4

14.3

(2.9)

TOTAL INTERNATIONAL

$

1,246

$

1,177

5.9

8.5

(2.6)

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Three Months Ended March 31, (continued)

(Unaudited; Amounts in millions)

Total

 % Change 

2014

2013

 Reported 

FXN

FX Impact

BD MEDICAL 

   Medical Surgical Systems

$

551

$

539

2.3

4.4

(2.1)

   Diabetes Care

251

232

8.1

10.4

(2.3)

   Pharmaceutical Systems

314

291

7.9

6.6

1.3

TOTAL

$

1,116

$

1,062

5.1

6.3

(1.2)

BD DIAGNOSTICS

   Preanalytical Systems

$

342

$

330

3.7

5.5

(1.8)

   Diagnostic Systems

311

329

(5.5)

(3.6)

(1.9)

TOTAL

$

653

$

659

(0.9)

1.0

(1.9)

BD BIOSCIENCES

$

302

$

279

8.2

10.2

(2.0)

TOTAL REVENUES

$

2,072

$

2,000

3.6

5.1

(1.5)

 

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Six Months Ended March 31,

(Unaudited; Amounts in millions)

United States

2014

2013

 % Change 

BD MEDICAL

   Medical Surgical Systems

$

502

$

485

3.6

   Diabetes Care

239

219

9.3

   Pharmaceutical Systems

133

134

(0.4)

TOTAL

$

875

$

838

4.5

BD DIAGNOSTICS

   Preanalytical Systems

$

335

$

329

1.7

   Diagnostic Systems

288

314

(8.3)

TOTAL

$

622

$

643

(3.2)

BD BIOSCIENCES 

$

177

$

173

2.3

TOTAL UNITED STATES

$

1,675

$

1,654

1.3

 

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Six Months Ended March 31, (continued)

(Unaudited; Amounts in millions)

International

 % Change 

2014

2013

 Reported 

FXN

FX Impact

BD MEDICAL

   Medical Surgical Systems

$

627

$

590

6.4

9.2

(2.8)

   Diabetes Care

275

256

7.5

11.0

(3.5)

   Pharmaceutical Systems

402

362

11.0

8.5

2.5

TOTAL

$

1,304

$

1,208

8.0

9.4

(1.4)

BD DIAGNOSTICS

   Preanalytical Systems

$

355

$

336

5.7

8.2

(2.5)

   Diagnostic Systems

348

332

4.7

8.0

(3.3)

TOTAL

$

703

$

668

5.2

8.1

(2.9)

BD BIOSCIENCES

$

404

$

371

8.9

10.6

(1.7)

TOTAL INTERNATIONAL

$

2,412

$

2,247

7.3

9.2

(1.9)

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS

Six Months Ended March 31, (continued)

(Unaudited; Amounts in millions)

Total

 % Change 

2014

2013

 Reported 

FXN

FX Impact

BD MEDICAL 

   Medical Surgical Systems

$

1,130

$

1,075

5.2

6.7

(1.5)

   Diabetes Care

514

475

8.3

10.2

(1.9)

   Pharmaceutical Systems

535

496

7.9

6.1

1.8

TOTAL

$

2,180

$

2,045

6.6

7.4

(0.8)

BD DIAGNOSTICS

   Preanalytical Systems

$

690

$

665

3.7

5.0

(1.3)

   Diagnostic Systems

636

646

(1.6)

0.1

(1.7)

TOTAL

$

1,325

$

1,311

1.1

2.6

(1.5)

BD BIOSCIENCES

$

581

$

544

6.8

8.0

(1.2)

TOTAL REVENUES

$

4,086

$

3,901

4.8

5.9

(1.1)

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

SAFETY REVENUES

(Unaudited; Amounts in millions)

Three Months Ended March 31,

 % Change 

2014

2013

 Reported 

FXN

FX Impact

TOTAL SAFETY REVENUES

   United States

$

287

$

287

-

-

-

   International

244

227

7.3

11.2

(3.9)

TOTAL

$

531

$

514

3.2

4.9

(1.7)

BY SEGMENT

   BD Medical

$

263

$

256

2.7

4.4

(1.7)

   BD Diagnostics

268

258

3.7

5.5

(1.8)

TOTAL

$

531

$

514

3.2

4.9

(1.7)

Six Months Ended March 31,

 % Change 

2014

2013

 Reported 

FXN

FX Impact

TOTAL SAFETY REVENUES

   United States

$

602

$

578

4.1

4.1

-

   International

486

447

8.7

11.6

(2.9)

TOTAL

$

1,088

$

1,026

6.1

7.3

(1.2)

BY SEGMENT

   BD Medical

$

548

$

508

7.8

9.1

(1.3)

   BD Diagnostics

540

517

4.4

5.6

(1.2)

TOTAL

$

1,088

$

1,026

6.1

7.3

(1.2)

 

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

FY2014 Quarter-to-Date Reconciliation of Non-GAAP Financial Measures

(Unaudited)

Three Months Ended March 31,

2014

2013

Growth

Foreign Currency Translation

Foreign Currency Neutral Change

Growth %

Foreign Currency Neutral Growth %

Reported Diluted Earnings per Share from Continuing Operations

$

1.45

$

1.39

$

0.06

$

(0.08)

$

0.14

4.3%

10.1%

Write-off of capitalized product software and, to a lesser extent, fixed assets primarily resulting from the discontinuance of an instrument product development program in the Biosciences segment ($20 million or $12 million after-tax)

0.06

-

Cost associated with the decision to early terminate a European distributor arrangement in the Diagnostics segment ($11 million or $8 million after-tax)

0.04

-

Gain from a cash distribution received from the sale of company, in which BD had a small equity ownership ($8 million or $5 million after-tax)

(0.03)

-

Adjusted Diluted Earnings per Share from Continuing Operations

$

1.53

$

1.39

$

0.14

$

(0.08)

$

0.22

10.1%

15.8%

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

FY2014 Year-to-Date Reconciliation of Non-GAAP Financial Measures

(Unaudited)

Six Months Ended March 31,

2014

2013

Growth

Foreign Currency Translation

Foreign Currency Neutral Change

Growth %

Foreign Currency Neutral Growth %

Reported Diluted Earnings per Share from Continuing Operations

$

2.82

$

2.74

$

0.08

$

(0.17)

$

0.25

2.9%

9.1%

Write-off of capitalized product software and, to a lesser extent, fixed assets primarily resulting from the discontinuance of an instrument product development program in the Biosciences segment ($20 million or $12 million after-tax)

0.06

-

Cost associated with the decision to early terminate a European distributor arrangement in the Diagnostics segment ($11 million or $8 million after-tax)

0.04

-

Gain from a cash distribution received from the sale of company, in which BD had a small equity ownership ($8 million or $5 million after-tax)

(0.03)

-

Adjusted Diluted Earnings per Share from Continuing Operations

$

2.90

$

2.74

$

0.16

$

(0.17)

$

0.33

5.8%

12.0%

The incremental impact in first quarter fiscal year 2014 of the medical device excise tax which went into effect in January 2013 under the U.S. Patient Protection and Affordable Care Act ($14 million or $9 million after-tax)

0.05

0.00

Adjusted Diluted Earnings per Share from Continuing Operations without incremental first quarter fiscal year 2014 impact of Medical Device Excise Tax

$

2.94

$

2.74

$

0.20

$

(0.17)

$

0.37

7.3%

13.5%

 

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

FY2014 Outlook Reconciliation

Reported

Basis

FX Impact

FXN Basis

Revenues - Full Year 2014 estimated growth

4.0% - 4.5%

(0.5%)

4.5% - 5.0%

Full Year

Full Year

2014

2013

% Increase

(estimated)

Reported Fully Diluted Earnings per Share 

from Continuing Operations

$

6.14 - 6.17

$

4.67

NM

Write-off of capitalized product software and, to a lesser extent, fixed assets primarily resulting from the discontinuance of an instrument product development program in the Biosciences segment

0.06

Cost associated with the decision to early terminate a European distributor arrangement in the Diagnostics segment

0.04

Gain from a cash distribution received from the sale of company, in which BD had a small equity ownership

(0.03)

Charge associated with the litigation settlement related to indirect purchaser antitrust class action cases

0.07

Charge associated with the unfavorable verdict returned in the antitrust and false advertising lawsuit filed against the Company by RTI

1.06

Non-cash pension settlement charge associated with lump sum benefit payments made from the Company's U.S. supplemental pension plan, as such payments exceeded the service and interest components of the plan's pension cost for the year. The charge also included settlement losses associated with certain foreign pension plans.

0.02

Adjusted Fully Diluted Earnings per Share 

from Continuing Operations

$

6.22 - 6.25

$

5.81

7.0% - 7.5%

FX Impact

(3.0%)

Adjusted FXN Growth

10.0% - 10.5%

Represents the incremental impact of the medical device excise tax in first quarter fiscal year 2014 (tax went into effect in January 2013 under the U.S. Patient Protection and Affordable Care Act)

(1.0%)

Adjusted FXN Growth (excluding the medical device excise tax)

11.0% - 11.5%

NM - Not Meaningful

FXN = Foreign Currency Neutral

SOURCE BD (Becton, Dickinson and Company)



RELATED LINKS

http://www.bd.com